MedTrace Logo

Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines

NCT01076478 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2010-02-26

No results posted yet for this study

Summary

To describe if there are differences in the subjective, objective and electrophysiologic parameters of diabetic polyneuropathies at baseline, four (4) weeks, eight (8) weeks, and twelve (12) weeks after Cilostazol therapy.

Conditions

  • Polyneuropathy

Interventions

DRUG

Cilostazol

100 mg, 200mg tablet Cilostazol

Sponsors & Collaborators

  • Otsuka Pharmaceutical, Inc., Philippines

    lead INDUSTRY

Principal Investigators

  • Raymond Rosales, MD, PhD · University of Santo Tomas Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Completion
2009-11-30

Countries

  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01076478 on ClinicalTrials.gov